Aminopeptidase activities as prospective urinary biomarkers for bladder cancer

Proteomics - Clinical Applications

Volumn 8, Issue 5-6, 2014, Pages 317-326

  Taylor, Jennifer M ^a,b   Yaneva, Mariana ^a   Velasco, Kevin ^a   Philip, John ^a   Erdjument Bromage, Hediye ^a   Ostrovnaya, Irina ^a   Lilja, Hans G ^a   Bochner, Bernard H ^a   Tempst, Paul ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Activity biomarkers; Aminopeptidases; Bladder cancer; Fluorescence; Urine

Indexed keywords

AMASTATIN; AMINOPEPTIDASE; BESTATIN; PROSTATE SPECIFIC ANTIGEN; PROTEOME; TUMOR MARKER;

AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HYDRATION; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION; URINALYSIS; ENZYMOLOGY; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; PROTEOMICS; URINARY BLADDER NEOPLASMS; URINE;

AMINOPEPTIDASES; BIOMARKERS, TUMOR; FEMALE; HUMANS; MALE; PROGNOSIS; PROSPECTIVE STUDIES; PROTEOMICS; URINARY BLADDER NEOPLASMS;

EID: 84902073201     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201300118     Document Type: Article

References (46)

1. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics 2013. CA Cancer J. Clin. 2013, 63, 11-30.
2. Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B. et al., The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003, 21, 1315-1330.
3. Konety, B. R., Joyce, G. F., Wise, M., Bladder and upper tract urothelial cancer. J. Urol. 2007, 177, 1636-1645.
4. Herr, H. W., Dotan, Z., Donat, S. M., Bajorin, D. F., Defining optimal therapy for muscle invasive bladder cancer. J. Urol. 2007, 177, 437-443.
5. Pisitkun, T., Johnstone, R., Knepper, M. A., Discovery of urinary biomarkers. Mol. Cell. Proteomics 2006, 5, 1760-1771.
6. Vrooman, O. P., Witjes, J. A., Urinary markers in bladder cancer. Eur. Urol. 2008, 53, 909-916.
7. Grossman, H. B., Soloway, M., Messing, E., Katz, G. et al., Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006, 295, 299-305.
8. Hajdinjak, T., UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol. Oncol. 2008, 26, 646-651.
9. Rifai, N., Gillette, M. A., Carr, S. A., Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24, 971-983.
10. Ransohoff, D. F., How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J. Clin. Epidemiol. 2007, 60, 1205-1219.
11. Egeblad, M., Werb, Z., New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2, 161-174.
12. Matrisian, L. M., Sledge, G. W., Jr., Mohla, S., Extracellular proteolysis and cancer: meeting summary and future directions. Cancer Res. 2003, 63, 6105-6109
13. Lopez-Otin, C., Matrisian, L. M., Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 2007, 7, 800-808.
14. Palermo, C., Joyce, J. A., Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol. Sci. 2008, 29, 22-28.
15. Villanueva, J., Martorella, A. J., Lawlor, K., Philip, J. et al., Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol. Cell. Proteomics 2006, 5, 1840-1852.
16. Villanueva, J., Shaffer, D. R., Philip, J., Chaparro, C. A. et al., Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 2006, 116, 271-284.
17. Villanueva, J., Nazarian, A., Lawlor, K., Yi, S. S. et al., A sequence-specific exopeptidase activity test for functional biomarker discovery. Mol. Cell. Proteomics 2008, 7, 509-518.
18. Gronborg, M., Kristiansen, T. Z., Iwahori, A., Chang, R. et al., Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol. Cell. Proteomics 2006, 5, 157-171.
19. Kulasingam, V., Diamandis, E. P., Proteomics analysis of conditioned media from three breast cancer cell lines. Mol. Cell. Proteomics 2007, 6, 1997-2011.
20. Lawlor, K., Nazarian, A., Lacomis, L., Tempst, P. et al., Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J. Proteome Res. 2009, 8, 1489-1503.
21. Turner, A. J., Membrane alanyl aminopeptidase, Barrett, A. J., Rawlings, N. D., Woessner, J. F. (Eds.), Handbook of Proteolytic Enzymes, 2nd. Ed., Academic Press, San Diego, 2004, pp. 289-294.
22. Wang, J., Cooper, M. D., Aminopeptidase A, Barrett, A. J., Rawlings, N. D., Woessner, J. F. (Eds.), Handbook of Proteolytic Enzymes, 2nd. Ed., Academic Press, San Diego, 2004, pp. 289-294.
23. Ikehara, Y., Ogata, S., Misumi, Y., Dipeptidyl-peptidase IV from rat liver. Methods Enzymol. 1994, 244, 215-227.
24. Underwood, R., Chiravuri, M., Lee, H., Schmitz, T. et al., Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. J. Biol. Chem. 1999, 274, 34053-34058.
25. Rao, N. V., Rao, G. V., Hoidal, J. R., Human dipeptidyl-peptidase I. Gene characterization, localization, and expression. J. Biol. Chem. 1997, 272, 10260-10265.
26. Adachi, J., Kumar, C., Zhang, Y., Olsen, J. V. et al., The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 2006, 7, R80.
27. Marimuthu, A., O'Meally, R. N., Chaerkady, R., Subbannayya, Y. et al., A comprehensive map of the human urinary proteome. J. Proteome. Res. 2011, 10, 2734-2743.
28. Rawlings, N. D., Barrett, A. J., Bateman, A., MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 2012, 40, D343-D350.
29. Lilja, H., Ulmert, D., Vickers, A. J., Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer. 2008, 8, 268-278.
30. Reiter, R. E., Gu, Z., Watabe, T., Thomas, G. et al., Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl. Acad. Sci. USA 1998, 95, 1735-1740.
31. Buckett, W. M., Luckas, M. J. M., Gazvani, M. R., Aird, I. A. et al., Seminal plasma lactoferrin concnetrations in normal and abnormal semen samples. J. Androl. 1997, 18, 302-304.
32. Dubbink, H. J., Verkaik, N. S., Faber, P. W., Trapman, J. et al., Tissue-specific and androgen-regulated expression of human prostate-specific transglutaminase. Biochem. J. 1996, 315, 901-908.
33. Xiao, F., Mirwald, A., Papaioannou, M., Baniahmad, A. et al., Secretoglobin 2A1 is under androgen control mediated by a peculiar binding site for Sp family transcription factors. Mol. Endocrinol. 2005, 19, 2964-2978.
34. Barrett, A. J., Rawlings, N. D., Woessner, J. F., Handbook of Proteolytic Enzymes, 2nd Ed., Academic Press, San Diego, 2004.
35. Shao, C., Li, M., Li, X., Wei, L. et al., A tool for biomarker discovery in the urinary proteome: a manually curated human urine protein biomarker set. Mol. Cell. Proteomics 2011, 10, M111.010975.
36. Kojima, K., Mihara, R., Sakai, T., Togari, A. et al., Serum activities of dipeptidyl-aminopeptidase II and dipeptidyl-aminopeptidase IV in tumor-bearing animals and in cancer patients. Biochem. Med. Metab. Biol. 1987, 37, 35-41.
37. Durinx, C., Neels, H., Van der Auwera, J. C., Naelaerts, K. et al., Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin. Chem. Lab. Med. 2001, 39, 155-159.
38. Carrera, M. P., Ramirez-Exposito, M. J., Valenzuela, M. T., Garcia, M. J. et al., Glutamyl- but not aspartyl-aminopeptidase activity is modified in serum of N-methyl nitrosourea-induced rat mammary tumours. Anticancer Res. 2004, 24, 801-805.
39. McPherson, R. A., Pincus, M. R., Henry's Clinical Diagnosis and Management by Laboratory Methods, 22nd Ed., Elsevier Saunders, Philadelphia, PA, 2011.
40. Perez, I., Varona, A., Blanco, L., Gil, J. et al., Increased APN/CD13 and acid aminopeptidase activities in head and neck squamous cell carcinoma. Head Neck 2009, 31, 1335-1340.
41. van Hensbergen, Y., Broxterman, H. J., Hanemaaier, R., Jorna, A. S. et al., Soluble aminopeptidase N in malignant and nonmalignant effusions and intratumoral fluid. Clin. Cancer Res. 2002, 8, 3747-3754.
42. Rangel, R., Sun, Y., Guzman-Rojas, L., Ozawa, M. G. et al., Impaired angiogenesis in aminopeptidase N-null mice. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 4588-4593.
43. Farrah, T., Deutsch, E. W., Omenn, G. S., Campbell, D. S. et al., A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol. Cell. Proteomics 2011, 10, M110.006353.
44. Budman, L. I., Kassouf, W., Steinberg, J. R., Biomarkers for detection and surveillance of bladder cancer. Can. Urol. Assoc. J. 2008, 2, 212-221.
45. Winkler, S. G., Lacomis, L., Philip, J., Erdjument-Bromage, H. et al., Isolation and mass spectrometry of transcription factor complexes. Methods 2002, 26, 260-269
46. Erdjument-Bromage, H., Lui, M., Lacomis, L., Grewal, A. et al., Micro-tip reversed-phase liquid chromatographic extraction of peptide pools for mass spectrometric analysis. J. Chromatogr. A 1998, 826, 167-181.